A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

OBJECTIVE: To assess the safety, tolerability, biological activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). METHODS: Patients with SELENA-SLEDAI score≥4 (N=449) were randomly assigned to belimumab (1, 4,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wallace, Daniel J., Stohl, William, Furie, Richard A., Lisse, Jeffrey R., McKay, James D., Merrill, Joan T., Petri, Michelle A., Ginzler, Ellen M., Chatham, W. Winn, McCune, W. Joseph, Fernandez, Vivian, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2758229/
https://ncbi.nlm.nih.gov/pubmed/19714604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.24699
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak